We are live on
!
Find out more
HEC
Hudson Executive Capital Portfolio holdings
AUM
$151M
1-Year Est. Return
60.14%
This Fund
S&P 500
This Quarter
Est. Return
-8.3%
1 Year Est. Return
+60.14%
3 Year Est. Return
+143.92%
5 Year Est. Return
+104.85%
10 Year Est. Return
+677.02%
AUM
$839M
AUM Growth
-$101M
(-11%)
Cap. Flow
-$19.7M
Cap. Flow
% of AUM
-2.35%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
1
Reduced
1
Closed
1
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Natera
NTRA
|
+$15.2M |
| 2 |
AKYA
Akoya BioSciences
AKYA
|
+$5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 81.52% |
| 2 | Technology | 8.32% |
| 3 | Healthcare | 2.5% |
Similar funds
SHF
CCM
DIG
BDS
MWA
WBCM
CAM
BA
Hudson Executive Capital's Q1 2023 Portfolio in Review
As of Q1 2023, Hudson Executive Capital held 7 positions worth $839M, down 11% from $939M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Hudson Executive Capital's Q1 2023 filing shows 1 increased, 1 reduced and 1 closed positions. The largest sale was Natera, an estimated $15.2M.
By sector, the portfolio is most concentrated in Financials at 82% of assets, up from 81% a quarter earlier, followed by Technology and Healthcare.
- Hudson Executive Capital's biggest Q1 2023 reduction was Akoya BioSciences, cutting an estimated $5M.
- Hudson Executive Capital fully exited Natera in Q1 2023, selling an estimated $15.2M.
- Hudson Executive Capital's ten largest holdings make up 100% of its $839M portfolio in Q1 2023.
- Hudson Executive Capital opened 0 new positions and closed 1 in Q1 2023.
- Hudson Executive Capital's portfolio value fell 11% quarter-over-quarter to $839M.
Based on Hudson Executive Capital's 13F filing for Q1 2023, filed 15 May 2023.